What is Kraig Biocraft Laboratories In's earnings per share (EPS)?

Kraig Biocraft Laboratories In (KBLB) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Kraig Biocraft Laboratories In Financials

KBLB

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows Kraig Biocraft Laboratories In (KBLB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.49x

For every $1 of reported earnings, Kraig Biocraft Laboratories In generates $0.49 in operating cash flow (-$1.8M OCF vs -$3.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-5.9x

Kraig Biocraft Laboratories In earns $-5.9 in operating income for every $1 of interest expense (-$3.4M vs $571K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$3.4M

YoY-11.5%

Kraig Biocraft Laboratories In's EBITDA was -$3.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 11.5% from the prior year.

Net Income

-$3.6M

YoY-6.6%

Kraig Biocraft Laboratories In reported -$3.6M in net income in fiscal year 2025. This represents a decrease of 6.6% from the prior year.

EPS (Diluted)

$0.00

Kraig Biocraft Laboratories In earned $0.00 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$1.8M

YoY+2.7%

Kraig Biocraft Laboratories In generated -$1.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 2.7% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

1.10B

10Y CAGR+4.5%

Kraig Biocraft Laboratories In had 1.10B shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$166K

YoY+0.8%

5Y CAGR+13.4%

10Y CAGR-9.1%

Kraig Biocraft Laboratories In invested $166K in research and development in fiscal year 2025. This represents an increase of 0.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$5K

YoY+27.2%

10Y CAGR-18.0%

Kraig Biocraft Laboratories In invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 27.2% from the prior year.

KBLB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$166K+0.8%	$164K-30.9%	$238K+34.8%	$176K-10.8%	$198K+123.5%	$88K
SG&A Expenses	$2.0M+12.1%	$1.7M+20.2%	$1.5M+76.2%	$825K-44.8%	$1.5M-57.5%	$3.5M
Operating Income	-$3.4M-9.8%	-$3.1M-17.6%	-$2.6M-23.3%	-$2.1M+23.1%	-$2.8M+39.1%	-$4.5M
Interest Expense	$571K+7.8%	$530K+9.3%	$485K+214.8%	$154K-35.3%	$238K+4245.9%	$5K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.6M-6.6%	-$3.4M-12.2%	-$3.0M+21.1%	-$3.8M+52.2%	-$8.0M-61.8%	-$5.0M
EPS (Diluted)	$0.00	$0.00	$0.00	$0.00	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9K-85.5%	$64K+167.6%	$24K	N/A	$25K-49.5%	$49K+67.9%	$29K	N/A
SG&A Expenses	$1.2M+248.8%	$344K+11.4%	$309K	N/A	$205K-81.3%	$1.1M+567.8%	$164K	N/A
Operating Income	-$1.4M-124.8%	-$638K-9.9%	-$580K	N/A	-$424K+71.5%	-$1.5M-231.2%	-$449K	N/A
Interest Expense	$144K+1.6%	$142K+1.2%	$140K	N/A	$133K+1.5%	$131K+0.7%	$130K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.5M0.0%	-$1.5M-151.6%	-$600K	N/A	-$433K+73.0%	-$1.6M-216.3%	-$508K	N/A
EPS (Diluted)	$0.00	$0.00	$0.00	N/A	$0.00	$0.00	$0.00	N/A

KBLB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$1.5M-53.4%	$3.2M-29.3%	$4.6M+51.3%	$3.0M+136.6%	$1.3M
Current Assets	N/A	$740K-71.2%	$2.6M-35.4%	$4.0M+68.4%	$2.4M+188.7%	$819K
Cash & Equivalents	N/A	$673K-73.6%	$2.6M-33.9%	$3.9M+64.0%	$2.4M+188.3%	$817K
Inventory	N/A	$7K0.0%	$7K+4.6%	$7K	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$9.7M+8.0%	$8.9M+10.5%	$8.1M-2.7%	$8.3M+5.9%	$7.9M
Current Liabilities	N/A	$9.6M+8.2%	$8.9M+10.1%	$8.1M-1.1%	$8.2M+9.6%	$7.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	-$8.1M-42.8%	-$5.7M-62.0%	-$3.5M+33.5%	-$5.3M+19.4%	-$6.6M
Retained Earnings	N/A	-$53.1M-6.8%	-$49.7M-6.5%	-$46.7M-9.0%	-$42.8M-23.1%	-$34.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$2.4M+48.1%	$1.6M+20.9%	$1.3M-12.6%	$1.5M-25.7%	$2.0M-8.7%	$2.2M-19.9%	$2.8M-14.2%	$3.2M
Current Assets	$1.6M+95.5%	$839K+85.3%	$453K-38.8%	$740K-40.2%	$1.2M-19.3%	$1.5M-25.5%	$2.1M-20.0%	$2.6M
Cash & Equivalents	$1.6M+99.3%	$785K+97.8%	$397K-41.0%	$673K-43.4%	$1.2M-21.8%	$1.5M-25.7%	$2.0M-19.8%	$2.6M
Inventory	$29K+322.2%	$7K0.0%	$7K0.0%	$7K0.0%	$7K0.0%	$7K0.0%	$7K0.0%	$7K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.3M+2.5%	$10.1M+2.0%	$9.9M+2.2%	$9.7M+2.9%	$9.4M+2.1%	$9.2M+2.0%	$9.0M+0.8%	$8.9M
Current Liabilities	$10.2M+1.5%	$10.0M+2.1%	$9.8M+2.2%	$9.6M+2.9%	$9.3M+2.1%	$9.1M+2.1%	$9.0M+0.8%	$8.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$8.0M+6.1%	-$8.5M0.0%	-$8.5M-4.0%	-$8.1M-10.8%	-$7.4M-5.5%	-$7.0M-11.7%	-$6.2M-9.4%	-$5.7M
Retained Earnings	-$55.9M-2.8%	-$54.4M-1.4%	-$53.7M-1.1%	-$53.1M-1.6%	-$52.2M-0.8%	-$51.8M-3.2%	-$50.2M-1.0%	-$49.7M

KBLB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.8M+2.7%	-$1.8M-47.8%	-$1.2M+34.1%	-$1.9M-4.8%	-$1.8M-43.5%	-$1.3M
Capital Expenditures	$5K+27.2%	$4K-33.7%	$6K+27.4%	$5K-94.8%	$97K	N/A
Free Cash Flow	-$1.8M+2.7%	-$1.8M-47.4%	-$1.3M+33.9%	-$1.9M+0.3%	-$1.9M	N/A
Investing Cash Flow	$438K+10431.2%	-$4K+33.7%	-$6K-27.4%	-$5K+99.1%	-$547K	N/A
Financing Cash Flow	$2.5M+7102.3%	-$35K+41.3%	-$60K-101.8%	$3.4M-12.5%	$3.9M+99.6%	$1.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$462K-4.2%	-$443K-2.0%	-$434K+15.2%	-$513K-57.1%	-$326K+36.1%	-$511K-4.3%	-$490K-49.4%	-$328K
Capital Expenditures	$0	N/A	N/A	N/A	N/A	N/A	N/A	$0
Free Cash Flow	-$462K	N/A	N/A	N/A	N/A	N/A	N/A	-$328K
Investing Cash Flow	$223K	N/A	N/A	N/A	N/A	N/A	N/A	$0
Financing Cash Flow	$1.0M+48.1%	$688K+334.9%	$158K	$0+100.0%	-$5K+65.0%	-$15K0.0%	-$15K0.0%	-$15K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KBLB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-225.8%-132.1pp	-93.7%-9.7pp	-84.0%+182.2pp	-266.3%+123.0pp	-389.2%
Current Ratio	N/A	0.08-0.2	0.29-0.2	0.49+0.2	0.29+0.2	0.11
Debt-to-Equity	N/A	-1.18+0.4	-1.57+0.7	-2.30-0.7	-1.57-0.4	-1.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-64.1%+30.8pp	-94.9%-49.3pp	-45.6%	N/A	-21.4%+51.0pp	-72.4%-54.0pp	-18.3%	N/A
Current Ratio	0.16+0.1	0.08+0.0	0.05-0.0	0.08-0.1	0.13-0.0	0.17-0.1	0.23-0.1	0.29
Debt-to-Equity	-1.30-0.1	-1.19-0.0	-1.16+0.0	-1.18+0.1	-1.28+0.0	-1.32+0.1	-1.44+0.1	-1.57
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Airboss Of Ameri ABSSF

$154.5M

Graphene Mfg Gro GMGMF

$196.0M

Nano One Materia NNOMF

$73.5M

Blue Biofuels Inc BIOF

$45.2M

Greystone Logist GLGI

$7.9M

Frequently Asked Questions

Is Kraig Biocraft Laboratories In profitable?

No, Kraig Biocraft Laboratories In (KBLB) reported a net income of -$3.6M in fiscal year 2025.

What is Kraig Biocraft Laboratories In's EBITDA?

Kraig Biocraft Laboratories In (KBLB) had EBITDA of -$3.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Kraig Biocraft Laboratories In's free cash flow?

Kraig Biocraft Laboratories In (KBLB) generated -$1.8M in free cash flow during fiscal year 2025. This represents a 2.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Kraig Biocraft Laboratories In's operating cash flow?

Kraig Biocraft Laboratories In (KBLB) generated -$1.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Kraig Biocraft Laboratories In's capital expenditures?

Kraig Biocraft Laboratories In (KBLB) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Kraig Biocraft Laboratories In spend on research and development?

Kraig Biocraft Laboratories In (KBLB) invested $166K in research and development during fiscal year 2025.

How many shares does Kraig Biocraft Laboratories In have outstanding?

Kraig Biocraft Laboratories In (KBLB) had 1.10B shares outstanding as of fiscal year 2025.

Are Kraig Biocraft Laboratories In's earnings high quality?

Kraig Biocraft Laboratories In (KBLB) has an earnings quality ratio of 0.49x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Kraig Biocraft Laboratories In cover its interest payments?

Kraig Biocraft Laboratories In (KBLB) has an interest coverage ratio of -5.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.